Ep71: Andy Plump

Episode Summary

Executive Summary: Takeda’s R&D chief Andrew Plump discusses how the company transformed into a global, innovation-driven pharma leader and rapidly mobilized during COVID-19 with work-from-home, trial pauses, and a plasma-based therapy program. He also reflects on pharma’s need to rebuild trust and on concrete steps leaders must take to address racial inequity through listening, diversity, and action.

Main Topics: Takeda’s transformation and global R&D footprint (Priority: 5/5): Plump explains how Takeda shifted from an older Japanese pharma into a global, innovation-led company centered in Cambridge, Massachusetts, with major acquisitions and a largely new pipeline. Early COVID-19 response and operational shutdown (Priority: 5/5): He describes the company’s rapid decisions in March to shut down globally, move employees home, pause many trials, and prioritize employee and patient safety. Plasma-derived therapy and the CoVIG Alliance (Priority: 5/5): Takeda leveraged its large plasma business to pursue hyperimmune immunoglobulin/convalescent plasma therapy, partnering with other plasma companies to share manufacturing and run a coordinated study. Industry collaboration during the pandemic (Priority: 4/5): Plump highlights unprecedented collaboration among pharma R&D leaders, who formed alliances to share best practices, consolidate efforts, and pursue repurposed and novel COVID treatments. Pharma reputation, trust, and public value (Priority: 4/5): He argues the industry must emerge from the pandemic with a better reputation, showing that it can act ethically and strategically to save lives and restore public trust. Racial justice, leadership, and diversity at Takeda (Priority: 5/5): Plump reflects on his own privilege, says leaders must listen to underrepresented voices, and outlines steps to improve inclusion and trial representation for Black and African American patients.

Key Arguments: Takeda is now fundamentally different from the company Plump joined in 2015: it is more global, more R&D-driven, and has a pipeline that is about 90% new. The company’s existing plasma capabilities made convalescent/hyperimmune immunoglobulin a logical COVID response, because Mother Nature had already identified neutralizing antibodies in recovered patients. Takeda acted early in the pandemic, shutting down globally in the second week of March and creating company-wide travel and work-from-home policies. COVID response required balancing employee safety, patient safety, ongoing essential trials, and ethical treatment of animal studies. Industry-wide collaboration was essential because no single company could solve the pandemic alone; alliances were formed to consolidate efforts and share best practices. The pharma industry should use COVID-19 to demonstrate its social value and rebuild a reputation that has been damaged by distrust. Racial inequity is not abstract: COVID exposed disproportionate unemployment and infection among Black Americans, and leaders must turn awareness into measurable action. Diversity is not just morally right; it improves performance, and companies should intentionally expand candidate pools and use stretch assignments to promote diverse leaders.

Data Points: Takeda age: 239 years old - Plump notes the company’s long history and resilience. Takeda global headcount: 50,000 employees - He describes the company’s current scale after transformation and acquisitions. Boston-area employee concentration: As many employees in greater Boston as in all of Japan - Highlights the shift of R&D strength toward Cambridge, Massachusetts. R&D scientist headcount: About 5,000 scientists - Approximate size of Takeda’s R&D organization. Boston-based R&D share: About two-thirds - Portion of R&D organization based in Boston. Pipeline newness: 90% of pipeline is new - Compared with the pipeline at the time Plump joined in 2015. Global shutdown timing: Second week of March - Takeda’s decision to close down globally during the early pandemic. COVID-focused spend in 2020: About a quarter of a billion dollars - Plump estimates company-wide spending on COVID-related work, largely clinical trials. Pandemic topic shift timing: Last 10 days - He says racial unrest displaced COVID as the top news story in that period. Pharma industry reputation comparison: Rivals tobacco or oil - Plump says pharma’s reputation is badly damaged and must improve. Clinical trial representation: Gender diversity is good; underrepresented minorities are poor - He says trial enrollment is strong for women but weak for Blacks and African Americans. Workday/routine: Wake up around five - Personal detail about his daily work-from-home routine and running schedule.

Pivotal Quotes: "It's not just philanthropic what we're doing, it's strategic." — Andy Plump: Describing pharma collaboration on COVID research and why it matters beyond altruism. "If we don't leave this pandemic with an entirely different reputation than the one that we've come in with, then we failed as an industry." — Andy Plump: On rebuilding trust in pharma through meaningful COVID action. "We have a huge problem and it's not going to go away overnight." — Andy Plump: On racial injustice and the need for sustained leadership action after the George Floyd protests.

Implications: The episode frames pharma as capable of rapid, high-impact public service when incentives align. For Takeda and peers, the test is whether pandemic collaboration and racial-justice commitments translate into lasting operational and cultural change.